SCHEMBL5518121

SCHEMBL5518121

FC1(F)[CH]CCC(F)(F)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL478015 0.73
SCHEMBL2904952 0.67
SCHEMBL828360 0.63
SCHEMBL6294988 0.61
SCHEMBL25392185 0.61
SCHEMBL287338 0.61
SCHEMBL38118 0.60
SCHEMBL17556551 0.59
SCHEMBL478011 0.59
SCHEMBL1148743 0.58

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070049600-A1 PTERIDINONES AS KINASE INHIBITORS WARNER-LAMBERT COMPANY 2007-03-01 US disclosed
US-7169778-B2 Pteridinones as kinase inhibitors WARNER-LAMBERT COMPANY (US) 2007-01-30 US disclosed
US-7053070-B2 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors WARNER-LAMBERT COMPANY (US) 2006-05-30 US disclosed
US-6951946-B2 Large scale synthesis of 1,2,4- and 1,3,4-oxadiazole carboxylates LEXICON PHARMACEUTICALS, INC. (US) 2005-10-04 US disclosed
EP-1173408-B1 PPAR-(GAMMA) AGONISTS AS AGENTS FOR THE TREATMENT OF TYPE II DIABETES COELACANTH CORP (US) 2005-07-20 EP disclosed
US-20050154211-A1 Large scale synthesis of 1,2,4- and 1,3,4- oxadiazole carboxylates KOLB HARTMUTH C (US) 2005-07-14 US disclosed
US-6891068-B2 Water as promoter in the nucleophilic substitution of chloride LEXICON PHARMACEUTICALS, INC. (US) 2005-05-10 US disclosed
US-6806380-B2 SUCH AS 1-METHOXY-2-(3-METHYLPHENYL)ETHANIMINE BY TREATING NITRILE WITH ANHYDROUS HYDROGEN CHLORIDE SOLUTION AND ANHYDROUS ALCOHOL LEXICON PHARMACEUTICALS, INC. 2004-10-19 US disclosed
US-20040171656-A1 Novel PPAR-gamma agonists as agents for the treatment of type II diabetes KOLB HARTMUTH C (US) 2004-09-02 US disclosed
EP-1409487-A1 PTERIDINONES AS KINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-04-21 EP disclosed
US-20030135050-A1 One step synthesis of 1,2,3-triazole carboxylic acids LEXICON PHARMACEUTICALS, INC. 2003-07-17 US disclosed
US-20030130286-A1 Pteridinones as kinase inhibitors DENNY WILLIAM ALEXANDER (NZ) 2003-07-10 US disclosed
US-20030073668-A1 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors BOOTH RICHARD JOHN (US) 2003-04-17 US disclosed
EP-1254137-A1 PYRIDO 2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2002-11-06 EP disclosed
EP-1173408-A1 PPAR-(GAMMA) AGONISTS AS AGENTS FOR THE TREATMENT OF TYPE II DIABETES Coelacanth Corporation (US) 2002-01-23 EP disclosed
EP-1150687-A2 METHODS FOR ANTI-TUMOR THERAPY Cellpath, Inc. (US) 2001-11-07 EP disclosed
WO-2001055147-A1 PYRIDO[2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-08-02 WO disclosed
WO-2001019825-A1 PTERIDINONES AS KINASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-03-22 WO disclosed
WO-2000063161-A1 PPAR-(GAMMA) AGONISTS AS AGENTS FOR THE TREATMENT OF TYPE II DIABETES COELACANTH CORPORATION (US) 2000-10-26 WO disclosed
WO-2000047215-A2 METHODS FOR ANTI-TUMOR THERAPY CELLPATH, INC. (US) 2000-08-17 WO disclosed